Market players were eager to push the start button on Nintendo (NTDOY 5.13%) stock as the trading week drew to a close. Shares of the storied Japanese video game company finished Friday up by more than 5% thanks in no small part to an analyst's price-target increase. That rise was in contrast to the S&P 500's dip of 0.4%.A bull gets more bullishBefore market open that day, JPMorgan Chase's Junko Yamamura lifted her fair value assessment on Nintendo's Japan-listed stock to 15,300 yen ($106.52) per share, up ...

Shares of Impinj (PI) have gained 52.5% over the past four weeks to close the last trading session at $117.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $149.50 indicates a potential upside of 27.2%.The mean estimate comprises eight short-term price targets with a standard deviation of $55.04. While the lowest estimate of $100 indicates a 14.9% decline from the current pri ...

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $10.65, gaining 35.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.05 indicates a 41.3% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.74. While the lowest estimate of $14.20 indicates a 33.3% increase from the current price level, the most optim ...

One of the most powerful catalysts for any stock is a substantial change in a researcher's price target. That was the dynamic behind the more than 2% gain of European Wax Center (EWCZ 1.94%) on Monday, as an analyst tracking the stock significantly upped her fair value assessment. The stock's rise far outpaced the less than 0.1% increase of the S&P 500 index that day. A 33% price target hikeWell before market open, Citigroup's Kelly Crago made the move. She upped her European Wax Center price target to $6 p ...

Core Viewpoint - JD.com's recent first-quarter results were generally well-received, but an analyst's price target cut led to a nearly 4% decline in stock price [1] Group 1: Analyst's Price Target Adjustment - Susquehanna International's Shyam Patil reduced JD.com's price target by over 10%, from $45 to $40 per share, while maintaining a neutral recommendation [2] - Despite the price target cut, Patil did not change his overall estimation of the stock [2] Group 2: Company Performance and Market Position - Patil praised JD.com's first-quarter performance, noting improvements in user experience that are driving user growth [4] - The company is well-positioned in the market and could benefit from expansion into new segments like food delivery [4] Group 3: Economic Concerns - The shaky state of the Chinese economy may limit JD.com's potential, according to Patil [5] - This economic uncertainty is expected to persist, influencing the analyst's price target reduction and neutral outlook [5] Group 4: Growth Potential - JD.com demonstrated encouraging year-over-year growth, particularly in its bottom line, and exceeded consensus analyst estimates [6] - There are indications that the Chinese macroeconomy might be in better shape than perceived, suggesting that JD.com should not be underestimated if it continues to improve its fundamentals [7]

Shares of Altimmune, Inc. (ALT) have gained 39.4% over the past four weeks to close the last trading session at $5.80, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.38 indicates a potential upside of 285.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $5.32. While the lowest estimate of $12 indicates a 106.9% increase from the cur ...

Astrazeneca (AZN) closed the last trading session at $67.30, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $86.07 indicates a 27.9% upside potential.The mean estimate comprises 10 short-term price targets with a standard deviation of $10.38. While the lowest estimate of $67 indicates a 0.5% decline from the current price level, the most optimistic analyst expects the ...

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has shown a significant price increase of 48.9% over the past four weeks, with a mean price target of $16.25 indicating a potential upside of 61.2% from the current price of $10.08 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets with a standard deviation of $5.66, indicating variability among analysts; the lowest estimate is $8 (20.6% decline), while the highest is $30 (197.6% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Consensus - There is growing optimism among analysts regarding BCRX's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 341.6% over the past month, with five estimates rising and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]

Shares of Upbound Group (UPBD) have gained 10.1% over the past four weeks to close the last trading session at $24.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $37.88 indicates a potential upside of 56.7%.The average comprises eight short-term price targets ranging from a low of $30 to a high of $50, with a standard deviation of $7.12. While the lowest estimate indicates ...

Group 1 - Birkenstock (BIRK) shares have increased by 17.3% over the past four weeks, closing at $51.46, with a mean price target of $68.15 indicating a potential upside of 32.4% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $95, with a standard deviation of $9.66, suggesting a variability in analyst estimates [2] - Analysts have shown a strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.8% over the past month, with three estimates going higher and no negative revisions [12] - Birkenstock currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [13]